Related Experiment Video
Updated: Sep 7, 2026
Associated Chromosome Trap for Identifying Long-range DNA Interactions
Published on: April 23, 2011
Concurrent BCR::ABL1 and SET::NUP214 fusions in blast-phase chronic myeloid leukemia
Meenakkshy Manoharan1, Fnu Alnoor2, Ping Yang2
1Division of Hematology, University of Miami Miller School of Medicine, Miami, FL, USA.
Introduction:
Concurrent atypical BCR::ABL1 transcripts and SET::NUP214 fusions are rare in chronic myeloid leukemia (CML) and may complicate disease classification and treatment decisions.
Methods:
Clinical, morphologic, cytogenetic, fluorescence in situ hybridization, and next-generation sequencing findings were reviewed in a patient with de novo myeloid blast-phase CML.
Results:
A 68-year-old man presented with hyperleukocytosis and was diagnosed with myeloid blast-phase CML harboring an atypical e13a3 BCR::ABL1 transcript and concurrent SET::NUP214 fusion. Single-agent dasatinib induced rapid remission, clearance of both fusion transcripts, and sustained molecular remission beyond 15 months.
Conclusion:
Concurrent atypical BCR::ABL1 and SET::NUP214 fusions are rare in myeloid blast-phase CML. Despite this molecular complexity, durable molecular remission was achieved with single-agent dasatinib.
